SCHEMBL20140464

SCHEMBL20140464

NC(=O)c1nc(Cc2ccccc2F)c2cnccn12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K3 P46734 2/20 0.42
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
MAPK14 Q16539 1/20 0.37
MAP3K14 Q99558 1/20 0.35
ALDH1A1 P00352 3/20 0.35
PLK1 P53350 1/20 0.35
ROCK2 O75116 1/20 0.35
GUCY1A1 Q02108 2/20 0.35
GUCY1B1 Q02153 2/20 0.35
LMNA P02545 1/20 0.34
KDM4E B2RXH2 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
BUB1 O43683 2/20 0.34
KCNH2 Q12809 1/20 0.34
AR P10275 1/20 0.34
MAOB P27338 1/20 0.34
PARP15 Q460N3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20140303 0.79 GUCY1A1 (0.44) MEN1KMT2ARXFP1ALDH1A1PLK1
SCHEMBL14746623 0.78 PDE4B (0.39) MAP2K3MEN1KMT2ARXFP1MAPK14
SCHEMBL20140398 0.76 CYP19A1 (0.34) MEN1KMT2ARXFP1ALDH1A1GUCY1A1
SCHEMBL21787231 0.71 AR (0.36) ALDH1A1GUCY1A1GUCY1B1KDM4EHPGD
SCHEMBL20139673 0.69 AR (0.34) ALDH1A1KDM4EAR
SCHEMBL9733462 0.67 GAA (0.48) MEN1KMT2AALDH1A1PLK1LMNA
SCHEMBL3571510 0.66 GUCY1A1 (0.54) MAP2K3MEN1KMT2AMAPK14ALDH1A1
SCHEMBL30450173 0.66 MEN1 (0.38) MEN1KMT2ARXFP1ALDH1A1LMNA
SCHEMBL20148917 0.65 AR (0.40) MEN1KMT2ARXFP1ALDH1A1PLK1
SCHEMBL2022562 0.64 MAPK1 (0.47) ALDH1A1LMNAKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435080-B2 sGC stimulators TISENTO THERAPEUTICS INC. (US) 2025-10-07 US disclosed
US-20220017515-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2022-01-20 US disclosed
US-20220017515-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2022-01-20 US disclosed
US-11180493-B2 SGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2021-11-23 US disclosed
US-11180493-B2 SGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2021-11-23 US disclosed
US-20200071318-A1 SGC STIMULATORS TISENTO THERAPEUTICS INC. 2020-03-05 US disclosed
US-20200071318-A1 SGC STIMULATORS TISENTO THERAPEUTICS INC. 2020-03-05 US disclosed
EP-3538520-A2 SGC STIMULATORS Cyclerion Therapeutics, Inc. (US) 2019-09-18 EP disclosed
WO-2018089330-A2 SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2018-05-17 WO disclosed
WO-2018089330-A2 SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200071318-A1 SGC STIMULATORS GUCY1A2, GMPS, PDE2A MAP2K3 3102/4885MEN1 4141/4885KMT2A 4675/4885
US-20220017515-A1 sGC STIMULATORS GUCY1A2, PRKG1, PDE2A MAP2K3 2911/4885MEN1 4168/4885KMT2A 4673/4885
US-12435080-B2 sGC stimulators GUCY1A2, PRKG1, PDE2A MAP2K3 2911/4885MEN1 4168/4885KMT2A 4673/4885
US-11180493-B2 SGC stimulators GUCY1A2, GMPS, PDE2A MAP2K3 3102/4885MEN1 4141/4885KMT2A 4675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.